Interaction Checker

Somatropin interactions

Somatropin (Genotropin, Humatrope, Norditropin) has 83 documented interactions across the FDA labels and fact sheets we index: 23 major, 60 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (23)

  • Azelastine and fluticasoneantihistamineMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • BeclomethasonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • BetamethasonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • BudesonidecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • Budesonide and formoterolcorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • CiclesonidecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • ClobetasolcorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • DeflazacortcorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • DesonidecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • FludrocortisonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • FlunisolidecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • FluocinonidecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • FluticasonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • Fluticasone and salmeterolcorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • HalobetasolcorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • HydrocortisonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • MethylprednisolonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • MometasonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • Olopatadine and mometasoneantihistamineMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • PrednisolonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • PrednisonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

  • TriamcinolonecorticosteroidMajor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Somatropin label, Drug interactions)

Moderate interactions (60)

  • AcarboseantidiabeticModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • AlogliptinDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Alogliptin and metforminDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • BexagliflozinSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • CanagliflozinSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Conjugated estrogensestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Conjugated estrogens and bazedoxifeneestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • DapagliflozinSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Dapagliflozin and metforminSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Desogestrel and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Drospirenone and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • DulaglutideGLP-1 receptor agonistModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • EmpagliflozinSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Empagliflozin and metforminSGLT2 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Esterified estrogens and methyltestosteroneestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • EstradiolestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Estradiol and dienogestoral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Estradiol and norethindroneestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Etonogestrel and ethinyl estradiolestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • ExenatideGLP-1 receptor agonistModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • FulvestrantestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • GlimepiridesulfonylureaModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Insulin aspartinsulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Levothyroxinethyroid hormoneModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • LinagliptinDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Linagliptin and metforminDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • LiraglutideGLP-1 receptor agonistModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • MetforminbiguanideModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Methimazoleantithyroid drugModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • MiglitolantidiabeticModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • NateglinidemeglitinideModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Norelgestromin and ethinyl estradiolestrogenModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Norethindrone and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Norgestimate and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • Norgestrel and ethinyl estradioloral contraceptiveModerate

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (Somatropin label, Drug interactions)

  • PioglitazonethiazolidinedioneModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Propylthiouracilantithyroid drugModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • RepaglinidemeglitinideModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • SaxagliptinDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Saxagliptin and metforminDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • SemaglutideGLP-1 receptor agonistModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • SitagliptinDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Sitagliptin and metforminDPP-4 inhibitorModerate

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (Somatropin label, Warnings and precautions)

  • Teriparatidethyroid hormoneModerate

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Somatropin label, Warnings and precautions)

  • TirzepatideGLP-1 receptor agonistModerate

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (Somatropin label, Warnings and precautions)

Check Somatropin against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.